![](/img/cover-not-exists.png)
In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: Comment on the article by Sfikakis et al
Ronald van Vollenhoven, Iva GunnarssonVolume:
52
Year:
2005
Language:
english
Pages:
2
DOI:
10.1002/art.21610
File:
PDF, 41 KB
english, 2005